Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma

International Journal of Clinical Oncology, 05/02/2012

Pirarubicin–based chemotherapy was comparable with gemcitabine–docetaxel as a second–line treatment for relapsed and refractory osteosarcoma, and it even seemed to show greater efficacy, with milder toxicity.

Print Article Summary Cat 2 CME Report